- Two cancer drugmaker rivals presented data on Monday about how combinations of their drugs, which harness the body's immune system to treat cancer, worked in treating a common form of lung cancer compared to traditional chemotherapy.
- Merck showed that its drug Keytruda in combination with chemotherapy cut the risk of death in lung cancer patients in half.
ADVERTISEMENT
2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)
The markets picked Merck as the winner based on its data lung cancer. Merck's stock was up about 3% on Monday while BMS was down about 5%.
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
Recommended articles
7 do's and don’ts of the Holy month of Ramadan
Top 5 sweetest celebrity mother-child relationships that stand out for us
International Women's Day: 5 Nigerian female celebrities championing women’s rights
Top 5 female directors in Nollywood
6 things that will break a Muslim's fast during Ramadan
5 benefits of fasting during Ramadan
Dos and don’ts of supporting Muslims during Ramadan
Here are common things people rarely dream about
5 young women who embody Y2K and alte fashion
ADVERTISEMENT